COMP <GO>
BGLC vs UNH // PIOTROSKI F-SCORE QUALITY
BioNexus Gene Lab Corp (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: BGLC 0
— UNH 10
▲ PIOTROSKI F-SCORE QUALITY LEADER: UNH
LAST: $0.98 (-7.79%) • MKT CAP: $2.9M
piotroski-score
2/9
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BGLC VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BGLC | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 14.60% | 88.57% | -73.97 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 11.47% | -46.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 6.48% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -39.90% | 4.82% | -44.72 | UNH | /operating-margins <GO> |
| Net Profit Margin | -40.20% | 3.14% | -43.34 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -21.90% | 6.46% | -28.36 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.12 | 3.12 | -1.00 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 2/9 | 7/9 | -5.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 24.5 | 59.2 | -34.71 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.9M | $368.83B | -$368.83B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BGLC REV | UNH REV | BGLC GROSS % | UNH GROSS % | BGLC FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.4M | $447.57B | 14.6% | 88.7% | -$1.9M | $16.07B |
| FY 2024 | $9.5M | $400.28B | 13.6% | 88.3% | -$2.3M | $20.70B |
| FY 2023 | $9.8M | $371.62B | — | 89.6% | -$1.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BGLC // BETA —
UNH // BETA 0.33